Видео ютуба по тегу Allo-Sct

Is allo-SCT still relevant in the immuno-oncology era for Hodgkin lymphoma?
Is allo-SCT still relevant in the immuno-oncology era for Hodgkin lymphoma?
Impact of conditioning intensity of allo-SCT for AML with molecular residual disease
Impact of conditioning intensity of allo-SCT for AML with molecular residual disease
Allo-SCT in older patients with MDS: selection, donors, and timing
Allo-SCT in older patients with MDS: selection, donors, and timing
HL: AUTO VS ALLO SCT, WILLIAM HWANG
HL: AUTO VS ALLO SCT, WILLIAM HWANG
Optimizing the timing of alloSCT in MPN-AP/BP: the importance of disease control
Optimizing the timing of alloSCT in MPN-AP/BP: the importance of disease control
allo-SCT improves survival following venetoclax and azacitidine therapy in AML
allo-SCT improves survival following venetoclax and azacitidine therapy in AML
Brissot: Comparing Matched-Sibling Donors in allo-SCT
Brissot: Comparing Matched-Sibling Donors in allo-SCT
At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
At what point should allo-SCT (or auto-allo-SCT) be considered for patients with MM?
How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?
How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for ALL?
Prevention, detection and treatment of AML relapse after allo-SCT
Prevention, detection and treatment of AML relapse after allo-SCT
Investigating relapse after allo-SCT in AML
Investigating relapse after allo-SCT in AML
Dr. Babak Nejati : Concepts and Future Direction of Allo-SCT
Dr. Babak Nejati : Concepts and Future Direction of Allo-SCT
When should we consider allo-SCT for patients with MDS?
When should we consider allo-SCT for patients with MDS?
Осложнения аллогенной трансплантации стволовых клеток (алло-ТСК)
Осложнения аллогенной трансплантации стволовых клеток (алло-ТСК)
GO-FLAG: bridge therapy to allo-SCT in R/R AML
GO-FLAG: bridge therapy to allo-SCT in R/R AML
How does CAR T-cell therapy compare with allo-SCT for treating R/R LBCL?
How does CAR T-cell therapy compare with allo-SCT for treating R/R LBCL?
The clearance of driver mutations following alloSCT impacts myelofibrosis disease outcomes
The clearance of driver mutations following alloSCT impacts myelofibrosis disease outcomes
Challenges of CAR-T bridging to allo-SCT
Challenges of CAR-T bridging to allo-SCT
Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?
Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?
Biomarkers for GvHD risk in allo-SCT
Biomarkers for GvHD risk in allo-SCT
Allogeneic Stem Cell Transplants
Allogeneic Stem Cell Transplants
FLT3 inhibitor maintenance after allo-SCT for AML
FLT3 inhibitor maintenance after allo-SCT for AML
allo-SCT in refractory AML: FLAMSA approaches
allo-SCT in refractory AML: FLAMSA approaches
How donor age impacts outcomes in patients with AML undergoing alloSCT
How donor age impacts outcomes in patients with AML undergoing alloSCT
Allo SCT approved
Allo SCT approved